FDA Approves GLEEVEC — Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals marked a decisive revenue milestone with the FDA approval of the blockbuster oncology agent Gleevec in 2003, a pivotal advancement for Imatinib Mesylate that positioned the drug as a generational sales generator and solidified Novartis' dominance in the targeted therapy sector.